Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nong Yang

Showing results (91-100 of 208) with videos related to

Pageof 21
Sort By:
BMC Medicine|October 19, 2021
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCYongchang Zhang, Liang Zeng, Xiangyu Zhang, et al.
Frontiers in Oncology|October 18, 2021
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI ResistanceLi Liu, Jingjing Qu, Jianfu Heng, et al.
BMC Medicine|September 13, 2021
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective studyYongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, et al.
NPJ Precision Oncology|April 1, 2022
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangementsYongchang Zhang, Zhe Huang, Liang Zeng, et al.
Microbiology Spectrum|November 17, 2021
Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant MetastasisHui Lu, Na L Gao, Fan Tong, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2023
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancerLiang Zeng, Yuling Zhou, Xiangyu Zhang, et al.
Cancer Medicine|November 7, 2022
The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancerChenglong Zhao, Jianghua Li, Yongchang Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2020
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancerXingzhou Peng, Xiaoyan Long, Li Liu, et al.
International Journal of Cardiology. Heart & Vasculature|February 5, 2024
Anti-inflammatory response-based risk assessment in acute type A aortic dissection: A national multicenter cohort studyHong Liu, Bing-Qi Sun, Zhi-Wei Tang, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2020
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersHaiyan Yang, Zhen Zhou, Li Lin, et al.
Pageof 21

Showing results (91-100 of 208) with videos related to

Sort By:
Pageof 21
BMC Medicine|October 19, 2021
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCYongchang Zhang, Liang Zeng, Xiangyu Zhang, et al.
Frontiers in Oncology|October 18, 2021
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI ResistanceLi Liu, Jingjing Qu, Jianfu Heng, et al.
BMC Medicine|September 13, 2021
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective studyYongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, et al.
NPJ Precision Oncology|April 1, 2022
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangementsYongchang Zhang, Zhe Huang, Liang Zeng, et al.
Microbiology Spectrum|November 17, 2021
Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant MetastasisHui Lu, Na L Gao, Fan Tong, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2023
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancerLiang Zeng, Yuling Zhou, Xiangyu Zhang, et al.
Cancer Medicine|November 7, 2022
The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancerChenglong Zhao, Jianghua Li, Yongchang Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2020
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancerXingzhou Peng, Xiaoyan Long, Li Liu, et al.
International Journal of Cardiology. Heart & Vasculature|February 5, 2024
Anti-inflammatory response-based risk assessment in acute type A aortic dissection: A national multicenter cohort studyHong Liu, Bing-Qi Sun, Zhi-Wei Tang, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2020
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersHaiyan Yang, Zhen Zhou, Li Lin, et al.
Pageof 21